Disclosed in the present disclosure is a biodegradable amphiphilic polymer containing disulfide in the side chain, a self-crosslinked polymeric vesicle thereof and an application in the targeted therapy of lung cancer. The polymer is obtained by an activity-controllable ring-opening polymerization based on a cyclic carbonate monomer containing a functional group of dithiolane ring, which has a controllable molecular weight and a narrow molecular weight distribution, and does not require processes of protection and deprotection; the polymer obtained by the ring-opening polymerization of the cyclic carbonate monomer of the present disclosure has biodegradability and can be used to control the drug release system, the prepared lung cancer-targeted reduction-sensitive reversibly-crosslinked polymeric vesicle as a nanomedicine carrier supports stable long circulation in vivo. However, it is highly enriched in lung cancer tissues, enter cells efficiently, and rapidly decrosslinks in the cells to release drugs, so as to kill cancer cells with high potency and specificity and inhibit the growth of tumor effectively without causing toxic and side effects.

A telodendrimer-nanolipoprotein particle (t-NLP), comprising one or more membrane forming lipids, one or more telodendrimers, and a scaffold protein and a Chlamydia major outer membrane protein (MOMP) comprising a MOMP hydrophobic region, and related compositions methods and systems.

The invention provides a blood substitute product comprising haemoglobin and a self-assembled microparticle having an acid having two or more acid groups and an organic base in a solvent. The particle is of micron scale. The microparticle may be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble or sparingly soluble in the hydrophilic solvent and the organic base is soluble in a hydrophilic solvent.

Methods of preparing polymersome-encapsulated functional protein suspensions may include thermally blending an amount of a block copolymer with an amount of a low molecular weight polyethylene glycol (PEG) for at least 30 minutes, mixing and cooling a resulting PEG/polymer formulation to room temperature, adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, and performing at least three dilution steps in which polymersomes that are generated are progressively saturated with the functional protein. The aliquot of the solution of the functional protein added may have a to the PEG/polymer sample of around 0.5:1 to 1.5:1 by volume, and the thermal blending may be performed at 90-100 C.

An encoding/decoding apparatus and method using a low-density parity-check code (LDPC code) is disclosed. Basic column group information, serving as a set of information regarding positions of rows with weight 1, is extracted from a reference column in each column group of a predetermined parity-check matrix. Column group information transforms the positions of rows with weight 1 into positions whose lengths are within a required parity length. A parity-check matrix is generated according to the generated column group information. Data is enclosed or decoded based on the generated parity-check matrix.

Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis. PEM constructs are developed that incorporate large amounts of iron-containing protein, possess high oxygen affinities, and demonstrate delayed nitric oxide binding. Such properties induce selective NME of tumors after extravasation, and will likely enhance the effect of VEGFR TKIs and/or mTOR inhibitors.

The present invention is directed to micro and nanosized capsule compositions and methods of using and making the capsule compositions. The capsule compositions comprise an outer layer of lipids and/or polymers and inner contents comprising semiconductor nanoparticles. The nanoparticles are either metal oxides or quantum dots and will produce reactive oxygen species when irradiated with either electromagnetic radiation or ultrasound. The reactive oxygen species will degrade the outer layer of the capsule and cause the release of the contents, including the reactive oxygen species, into the local environment. The contents may optionally include cancer treating agent, water treating agents, antimicrobials, imaging and/or contracting agents. The outer layer may be further coated to protect it from environmental factors and/or be conjugated with a targeting molecule to increase delivery to a target.

The present disclosed a preparation method preparation method for, and use of, a small molecular drug-loaded polymer vesicle. The small molecular drug-loaded polymer vesicle is prepared by assembling an amphiphilic block polymer and a small molecular drug; or is obtained by assembling and cross-linking the amphiphilic block polymer and a functionalized amphiphilic block polymer, loading the small molecular drug, and then reacting with a targeting monoclonal antibody. The vesicle system has many unique advantages, including small size, simple and controllable preparation, excellent biocompatibility, high stability of circulation in vivo, strong specific selectivity of tumor cells, high intracellular drug release rate, remarkable effect of tumor growth inhibition, etc. Therefore, the vesicle system is expected to become a simple and multi-functional nano-platform for efficient and specific targeted delivery of vincristine sulfate to multiple myeloma cells.

The present document relates to amphiphilic poly(monoglycerol acrylate) (PMGA) polymers, comprising an hydrophilic repeating unit of monoglycerol acrylate and one or more biodegradable hydrophobic group and their use and methods of use in the delivery of bioactive agents. Additionally, the invention provides a method for preparing monoglycerol acrylate-based polymers.

The instant disclosure is directed to compositions comprising an encapsulated spheroid, and methods of making and using the same. A composition may comprise a spheroid comprising a plurality of cells and aminoglycoside antibiotic-derived hydrogel beads, wherein the spheroid is encapsulated by the aminoglycoside antibiotic-derived hydrogel beads to form an encapsulated spheroid. A method may comprise administering the composition to a subject in need thereof. Another method may comprise administering a compound to the encapsulated spheroid. A method of creating an encapsulated spheroid may comprise coating a surface with an aminoglycoside antibiotic-derived hydrogel, culturing a plurality of cells on the surface, thereby creating a spheroid, and encapsulating the spheroid with a plurality of aminoglycoside antibiotic-derived hydrogel beads.